Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Metformin does not increase SGA risk in gestational diabetes
Last updated September 4, 2026
Key finding
Mothers of SGA infants were more likely to develop pre-eclampsia (18.2% vs 2.0%, p =0.001).
This study compared the effects of metformin versus placebo in treating gestational diabetes, finding no significant differences in several perinatal outcomes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared the effects of metformin versus placebo in treating gestational diabetes, finding no significant differences in several perinatal outcomes.
Clinical relevance
Understanding the effects of metformin in gestational diabetes is crucial for guiding treatment decisions. While it may not improve perinatal outcomes, the increased risk of maternal complications raises concerns about its safety and necessitates careful consideration in clinical practice.
Keep in mind
Limited generalizability due to specific population characteristics. Potential unmeasured confounders affecting outcomes. Small sample size may limit the robustness of findings.
Published in
Journal Reference
Publication details and source links for this paper.
Fidelma D, Christine N, Alberto A, et al. Metformin vs placebo in treating gestational diabetes: a secondary analysis of the EMERGE trial. Diabetologia. 2024;67(12):2660-2666. doi:10.1007/s00125-024-06252-y
Main Effects
No significant difference in preterm birth rates between metformin (20.0%) and placebo (14.3%, p=1.00).
Caesarean delivery rates were similar: 50.0% for metformin vs 28.6% for placebo (p=0.25).
Higher incidence of maternal pre-eclampsia in metformin group (18.2% vs 2.0%, p=0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Metformin and Caesarean delivery, Maternal gestational hypertension, Maternal pre-eclampsia, and 3 more.
This study contributes evidence to
Primary intervention
Metformin
Primary outcomes
- Caesarean delivery
- Maternal gestational hypertension
- Maternal pre-eclampsia
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 59
1
Related topics
6
Evidence pairs
35
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
Metformin
matched_intervention
Core evidence
Study findings
The primary outcomes reported in this study.
Maternal gestational hypertension
Metformin → Maternal gestational hypertension
Metformin → Maternal gestational hypertension
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerNeonatal care unit admission
Metformin → Neonatal care unit admission
Metformin → Neonatal care unit admission
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerRate of preterm delivery (<37 weeks)
Metformin → Rate of preterm delivery (<37 weeks)
Metformin → Rate of preterm delivery (<37 weeks)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerSmall for gestational age infants
Metformin → Small for gestational age infants
Metformin → Small for gestational age infants
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- No significant difference in neonatal care unit admissions (13.3% vs 42.9%, p=0.27).
- Increased risk of gestational hypertension in metformin group (22.7% vs 5.4%, p=0.005).
- Overall effectiveness of metformin remains unclear based on outcomes.
Who this applies to
- Pregnant individuals diagnosed with gestational diabetes.
- Women at risk for gestational diabetes due to obesity or family history.
Keep in Mind
- Findings may not apply to all populations due to study design.
- Results highlight the need for careful monitoring of maternal health.
- Further research is needed to explore long-term effects of metformin.
Between the Lines
- Limited generalizability due to specific population characteristics.
- Potential unmeasured confounders affecting outcomes.
- Small sample size may limit the robustness of findings.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and Caesarean delivery, Metformin Therapies and Maternal gestational hypertension.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Metformin Therapies → Caesarean delivery
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Caesarean delivery Evidence Hub
All studies measuring Caesarean delivery
1 studies
outcome_hubMeasures Caesarean delivery as a key outcome.
Maternal gestational hypertension Evidence Hub
All studies measuring Maternal gestational hypertension
1 studies
outcome_hubMeasures Maternal gestational hypertension as a key outcome.
Metformin Therapies Evidence Hub
All studies on Metformin Therapies
1 studies
intervention_hubContributes to Metformin Therapies evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Metformin and Caesarean delivery
Intervention: MetforminOutcome: Caesarean delivery
1 results
All studies on Metformin and Maternal gestational hypertension
Intervention: MetforminOutcome: Maternal gestational hypertension
1 results
All studies on Metformin
Intervention: Metformin
1 results
All studies measuring Caesarean delivery
Outcome: Caesarean delivery
1 results
All studies measuring Maternal gestational hypertension
Outcome: Maternal gestational hypertension
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Metformin improve maternal gestational hypertension?
Emerging Evidence
Metformin appears to improve maternal gestational hypertension.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Maternal gestational hypertension
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Metformin improve maternal pre-eclampsia?
Emerging Evidence
Metformin appears to improve maternal pre-eclampsia.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Maternal pre-eclampsia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Metformin improve caesarean delivery?
Emerging Evidence
Current evidence does not show a clear benefit of Metformin for caesarean delivery.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Caesarean delivery
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Metformin improve neonatal care unit admission?
Emerging Evidence
Current evidence does not show a clear benefit of Metformin for neonatal care unit admission.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Neonatal care unit admission
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Dietary Modulation of Gut Microbiota in PrediabetesVildagliptin and Metformin Improve Glycemic Control in Type 2 DiabetesEarly use of effective therapies may improve diabetes outcomesPremeal metformin improves postmeal glucose control in diabetes.Metformin improves fat oxidation and reduces visceral fat in type 2 diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.